miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

View original at globenewswire.com
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight New York, USA, Jan…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The market size for atherosclerotic cardiovascular disease was USD 23 billion in the leading markets in 2024

    80% confidence

  • Despite strong clinical validation, real-world adoption challenges for existing PCSK9 inhibitors have opened the door to next-generation therapies

    80% confidence

  • The dynamics of the ASCVD market are expected to change in the coming years due to the launch of emerging therapies

    80% confidence

  • The United States accounted for approximately 75% of the total ASCVD market size in the 7MM in 2024

    80% confidence

  • While marketed therapies have cemented PCSK9 inhibition as a powerful intervention, uptake challenges have left room for innovation. This gap is now fueling a new wave of competition with oral, long-acting, and gene-editing approaches.

    80% confidence

  • In the United States, systemic inflammation-associated ASCVD cases were estimated at approximately 17 million in 2024

    80% confidence

  • The ASCVD clinical trial landscape is undergoing a notable transition, moving beyond traditional LDL-C-focused strategies toward more targeted, mechanism-based interventions for cardiovascular risk reduction

    80% confidence

  • The advancement of late-stage candidates such as Amgen's olpasiran and Ionis/Novartis' pelacarsen highlights the increasing clinical and commercial emphasis on lipoprotein(a), a genetically determined and long-overlooked contributor to residual ASCVD risk

    80% confidence

  • In 2024, the total diagnosed prevalent cases of ASCVD across the 7MM were approximately 65 million, and this burden is projected to rise over the forecast period

    80% confidence

  • The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025-2034) at a CAGR of 4.9%

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight — Source | Via News | es.VIA.NEWS